Compare FOFO & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | LPCN |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.1M |
| IPO Year | 2025 | 2011 |
| Metric | FOFO | LPCN |
|---|---|---|
| Price | $2.70 | $2.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.0K | ★ 39.7K |
| Earning Date | 03-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.75 | $1.81 |
| 52 Week High | $68.00 | $12.37 |
| Indicator | FOFO | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 41.67 |
| Support Level | $2.33 | $1.99 |
| Resistance Level | $2.88 | $2.30 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 77.36 | 29.11 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.